Enhancement of Oncolytic Activity of oHSV Expressing IL-12 and Anti PD-1 Antibody by Concurrent Administration of Exosomes Carrying CTLA-4 miRNA

doi 10.35248/2471-9552.19.5.154
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Longdom Group

Related search

Effect of in Vivo Administration of Anti-Ctla-4 Monoclonal Antibody and IL-12 on the Induction of Low-Dose Oral Tolerance

Clinical and Experimental Immunology
AllergyImmunology
2002English

Intestinal Microbiota Predict Response and Toxicities During Anti-Pd-1/Anti-Ctla-4 Immunotherapy

Pathology
Forensic MedicinePathology
2020English

CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients

JCI insight
Medicine
2018English

Comment on ‘Efficacy and Toxicity of Treatment With the Anti-Ctla-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-Pd-1 Therapy’

British Journal of Cancer
Cancer ResearchOncology
2017English

The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (Anti-Pd-1/Pd-L1 Plus Anti-Ctla-4): A Systematic Review and Meta-Analysis

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Enhancement of Anti-Tumor Immunity Through Local Modulation of CTLA-4 and GITR by Dendritic Cells

European Journal of Immunology
AllergyImmunology
2011English

Ipilimumab: An Anti-Ctla-4 Antibody for Metastatic Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2011English

P105 Computational Design of IgG-like Tetra-Specific Antibody Targeting EGFR/VEGF/PD-1/CTLA-4 Against NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Interdependent IL-7 and IFN-γ Signalling in T-Cell Controls Tumour Eradication by Combined Α-Ctla-4+α-Pd-1 Therapy

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy